CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 192 enrolled
Drug / intervention
GSK Biologicals' influenza vaccine GSK2186877A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00765076
NCT00765076Phase 3Completed
CompareCT.gov

Observer-blind Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects

GlaxoSmithKline·interventional·Posted Oct 2, 2008·Updated Jul 31, 2018

In Brief

A Phase 3 clinical trial evaluating GSK Biologicals' influenza vaccine GSK2186877A and GSK Biologicals' Fluarix for Influenza. Completed, enrolled 192 participants across 4 sites in 2 countries.

Detailed Summary

This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSpain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2, 2008
Enrollment StartOct 16, 2008
Primary CompletionDec 4, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.8 years ago

Interventions

GSK Biologicals' influenza vaccine GSK2186877Abiological

One intramuscular injection at Day 0

GSK Biologicals' Fluarixbiological

One intramuscular injection at Day 0